Influence of time to first therapy (TTFT) variable on survival outcomes of neoadjuvant chemotherapy versus upfront surgery approach in resectable pancreatic ductal adenocarcinoma

被引：0
|
作者：
Sousa, Aryanna
Pena, Paola
Kwon, Steve
机构：
[1] Roger Williams Canc Outcomes Res & Equ RWCORE Ctr, Providence, RI USA
[2] Roger Williams Med Ctr, Providence, RI USA
[3] Rush Univ Med Ctr, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [1] Relationship of Time to First Therapy and Survival Outcomes of Neoadjuvant Chemotherapy Versus Upfront Surgery Approach in Resectable Pancreatic Ductal Adenocarcinoma
    Al Masad, Qusai
    Sousa, Aryanna
    Pena, Paola
    Sammartino, Cara J.
    Somasundar, Ponnandai
    Abdelfattah, Thaer
    Espat, N. Joseph
    Calvino, Abdul S.
    Kwon, Steve
    JOURNAL OF SURGICAL RESEARCH, 2025, 306 : 111 - 121
  • [2] Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma
    Shin, Kyung In
    Yoon, Min Sung
    Kim, Jee Hoon
    Jang, Won Joon
    Leem, Galam
    Jo, Jung Hyun
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Hwang, Ho Kyoung
    Kang, Chang Moo
    Kim, Seung-seob
    Park, Mi-Suk
    Lee, Hee Seung
    Bang, Seungmin
    CANCER MEDICINE, 2024, 13 (22):
  • [3] Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma
    Sugawara, Toshitaka
    Rodriguez Franco, Salvador
    Sherman, Samantha
    Torphy, Robert
    Colborn, Kathryn
    Franklin, Oskar
    Ishida, Jun
    Grandi, Samuele
    Al-Musawi, Mohammed
    Gleisner, Ana
    Schulick, Richard
    Del Chiaro, Marco
    ANNALS OF SURGERY, 2024, 279 (02) : 331 - 339
  • [4] PROPENSITY SCORE MATCHED ANALYSIS OF NEOADJUVANT THERAPY VERSUS UPFRONT SURGERY FOR RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
    Yoon, Minsung
    Lee, Hee Seung
    Bang, Seungmin
    GASTROENTEROLOGY, 2020, 158 (06) : S867 - S867
  • [5] Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma Reply
    Saharia, Ashish
    Potter, Lucy
    Baio, Flavio
    Elshawwaf, Mahmoud
    Abdelrahim, Maen
    Heyne, Kirk
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (10): : 753 - 754
  • [6] Bayesian Network Meta-Analysis of Upfront Surgery versus Neoadjuvant Therapy for Potentially Resectable Pancreatic Ductal Adenocarcinoma
    Bradley, Alison
    Van der Meer, Robert
    McKay, Colin
    BRITISH JOURNAL OF SURGERY, 2021, 108 : 61 - 61
  • [7] NEOADJUVANT CHEMOTHERAPY VERSUS UPFRONT SURGERY IN RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA: A NATIONAL CANCER DATABASE INTENTION-TO-TREAT ANALYSIS
    Buchheit, Joanna T.
    Burke, Cynthia E.
    Vining, Charles C.
    Brahmbhatt, Rushin D.
    Peng, June S.
    GASTROENTEROLOGY, 2024, 166 (05) : S1815 - S1816
  • [8] Neoadjuvant chemotherapy vs upfront resection: A challenging choice in resectable pancreatic ductal adenocarcinoma
    Fekrmandi, Fatemeh
    Hagerty, Brendan
    Liu, Qian
    Schneider, Tyce
    Malik, Nadia
    Fountzilas, Christos
    Kukar, Moshim
    Cherkassky, Leonid
    Calvo, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 620 - 620
  • [9] Survival After Neoadjuvant Chemotherapy in Borderline Resectable Disease is Similar to That of Upfront Resectable Pancreatic Adenocarcinoma
    Chawla, A.
    Molina, G.
    Pak, L.
    Wang, J.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S150 - S150
  • [10] Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy versus Surgery First Approach
    Hyman, David W.
    Almerey, Tariq
    Mujkanovic, Amer
    Hammons, Isaac
    Tice, Mary
    Stauffer, John A.
    AMERICAN SURGEON, 2022, 88 (08) : 1868 - 1874
12345